Research

Researcher setting up genetic samples and primers for polymerase chain reaction

Parkinson's Disease and other movement disorders

Hope through research

The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.

PPMI

Healthy Cohort

Brief summary: The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Status: Recruiting - For more information, review the study record:

https://clinicaltrials.gov/study/NCT04477785?term=robert%20hauser&rank=9

Illustration of images of genes (red, green and blue spots) are superimposed on images of multi-well plates

STEM PD

SNS-PD-002

Brief summary: This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.

Status: Recruiting - For more information, review the study record:

https://clinicaltrials.gov/study/NCT04797611?term=SNS-PD-002&rank=1&limit=10

Our Current Clinical Trials

microscope

Enterin - EUA

ID: NCT04483479

Brief summary: This study will be conducted as an open-label safety follow-on to a multi-center, double-blind, randomized study. All subjects who participated in the randomized study will be offered participation in this unblinded, single-arm, safety study. Approximately 50 subjects will be entered into the study and ENT-01 will be administered daily in escalating doses followed by a fixed dose for 12 weeks. Each subject will participate for approximately 20 weeks; dosing duration will be approximately 14 weeks.

Status: Recruiting - For more information, review the study record: 

Link: https://clinicaltrials.gov/study/NCT04483479

M20-098

ID: NCT04750226

Brief summary: Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Status: Active, not recruiting

Link: https://clinicaltrials.gov/study/NCT04750226?rank=1

                                       Orchestra

                                                                               ID: NCT04658186

                                                                               Brief summary: A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study                                                                                   Participants With Early-stage Parkinson's Disease (ORCHESTRA)

                                                                              Status: Recruiting - For more information, review the study record: 

                                                                              Link: https://clinicaltrials.gov/study/NCT04658186

Padova

ID: NCT04777331

Brief summary: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Status: Recruiting - For more information, review the study record: 

Link: https://clinicaltrials.gov/study/NCT04777331?tab=results

Human breast cancer cells

LUMA

Biogen, 283PD201

Brief summary: A Study to Assess the Safety of BIIB122 Tablets and if it Can Flow the Worsening of Early-Stage Parkinson’s Disease in participants between the Ages of 30 and 80 (LUMA)

Status: Recruiting - For more information, review the study record:

https://clinicaltrials.gov/study/NCT05348785?term=robert%20hauser&rank=7

Apprise - PKG

ID: NCT01141023

Brief summary: Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI)

Status: Recruiting - For more information, review the study record:

Link: https://clinicaltrials.gov/study/NCT01141023

Patagonia

JZP 385-202

Brief summary: A study of suvecaltamide in adults with moderate to severe residual tremor in Parkinson’s Disease

Status: Maintaining - For more information, review the study record:

https://clinicaltrials.gov/study/NCT05642442?term=jzp385-202&rank=1

Inhibikase

IKT-148009-201

Brief summary: This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease.

Status: Maintaining - For more information, review the study record:

https://www.clinicaltrials.gov/study/NCT05424276?spons=Inhibikase%20Therapeutics,%20Inc.&rank=2

Support

Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.

 

To support our mission, click here or reach out to Ashley Messer at amesser2@usf.edu or (813) 389-2845.